- VivaGel® rBV phase 3 trials: Data collation and routine quality control review are complete, with the statistical analysis plan and bio-statistical programming in the process of being finalised, prior to unblinding the data. Trial results are expected to be released in late July/early August.
early - mid - late month
early - 1st to 10th
mid - 10th to 20th
late - 20th to 30th/31st
So based on the above definition we are now in the expected release time line
ie
20th of July to 10th of August
Let's start that time clock countdown again, page-39
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.90M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83046 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |